Antibiotic resistance and new drugs in urologic setting: what we need to know?
Urinary tract infections (UTIs) are among the most frequent infectious diseases, and represent an important public health problem with a substantial economic burden. In recent years the chemoresistance of the main uropathogens has significantly increased worldwide. Extended spectrum beta-lactamase (ESBL) production and multi-drug resistant (MDR) clones of Escherichia coli and Klebsiella pneumoniae are limiting available treatment options. Carbapenems and aminoglycosides are still effective in complicated UTI. New beta-lactam combinations such as ceftolozane-tazobactam and ceftazidime-avibactam may be highly useful in treating severe infections while contributing to the carbapenem sparing strategy. For uncomplicated UTI, within older antibiotics, fosfomycin trometamol may be considered a first-choice drug since it is still retaining a good activity against MDR uropathogens. On the other hand, there are extensive data showing that the administration of antimicrobials according to pharmacokinetic/pharmacodynamic (PK/PD) parameters improves the possibility of a positive clinical outcome, particularly in severely ill patients. Evidence is growing that when PK/PD parameters are used to target not only clinical cure.
This article discusses the PK/PD characteristics of antimicrobial agents for the treatment of UTIs, and the pharmacological and therapeutic strategies for limiting or preventing bacterial resistance.
GrabeMBartolettiRBjerklund JohansenTECaiTÇekMKövesBet al. Guidelines on Urological Infections. EAU2015.
2.
Flores-MirelesALWalkerJNCaparonMHultgrenSJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol2015; 13(5): 269-84.
3.
GuptaKHootonTMNaberKGet al. Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis2011; 52(5): e103-2.
MittalRAggarwalSSharmaSChhibberSHarjaiK. Urinary tract infections caused by Pseudomonas aeruginosa: a minireview. J Infect Public Health2009; 2(3): 101-11.
6.
BoyleDPZembowerTR. Epidemiology and management of emerging drug-resistant gram-negative bacteria: extended-spectrum β-lactamases and beyond. Urol Clin North Am2015; 42(4): 493-505.
7.
MeierSWeberRZbindenRRuefCHasseB. Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection2011Aug; 39(4): 333-40.
8.
BouchillonSHobanDJBadalRHawserS. Fluoroquinolone resistance among gram-negative urinary tract pathogens: global smart program results, 2009-2010. Open Microbiol J2012; 6: 74-8.
9.
PelegAYHooperDC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med2010; 362(19): 1804-13.
10.
HernándezCFehérCSorianoAet al. Clinical characteristics and outcome of elderly patients with community-onset bacteremia. J Infect2015; 70(2): 135-43.
11.
CarrërANordmannP. CTX-M-15-producing Klebsiella pneumoniae: a change in the epidemiology of ESBL. Pathol Biol (Paris) 2011; 59(6): e133-5.
12.
Munoz-PriceLSPoirelLBonomoRAet al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis2013; 13(9): 785-96.
13.
SaderHSFarrellDJFlammRKJonesRN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the Sentry Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents2014; 43(4): 328-34.
14.
BushK. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents2015; 46(5): 483-93.
15.
ShlaesDM. New β-lactam-β-lactamase inhibitor combinations in clinical development. Ann N Y Acad Sci2013; 1277: 105-14.
16.
Levy HaraGGouldIEndimianiAet al. Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: recommendations from an International Working Group. J Chemother2013; 25(3): 129-40.
17.
BaderMSLoebMBrooksAA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med2017; 129(2): 242-58.
18.
AdembriCNovelliA. Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance. Clin Pharmacokinet2009; 48(8): 517-28.
19.
CraigWA. Selecting the antibiotic. Proceedings of a Symposium. Sonoma 281993; (Suppl 1): 26-27/1.
20.
CraigWAGudmundssonS. Postantibiotic effect. In: LorianV ed. Antibiotics in laboratory medicine, 3rd ed. Baltimore, MD: Williams and Wilkins1991; 403-31.
21.
CraigWA. Post-antibiotic effects in experimental infection models; relationship to in vitro phenomena and to treatment of infections in man. J Antimicrob Chemother1993; 31(Suppl D): 149-58.
22.
MazzeiTNovelliAMiniEPeritiP. Concentrazioni plasmatiche e tissutali degli antibiotici: qual è il loro valore predittivo?Ann Ital Med Int1992; 7(Suppl 3): 67-73.
23.
RinaldiSNovelliADe GaudioAR. Systemic antibiotics. In: van SaeneHKFSilvestriLde la CalMA, eds. Infection Control in Intensive Care Unit, 2nd ed. Springer Verlag2005.
24.
CraigWA. Pharmacokinetics/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis1998; 26: 1-10.
25.
PrestonSLDrusanoGLBermanALet al. Pharmacodynamics of levofloxacin. A new paradigm for early clinical trials. J Am Med Assoc1998; 279: 125-9.
26.
De RykeCALeeSYKutiJLNicolauDP. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. Drugs2006; 66(1): 1-14.
27.
ScaglioneFBertazzoni MinelliEDe SarroAet al. The Charta of Milan: basic criteria for the appropriate and accurate use of antibiotics: recommendations of the Italian Society of Chemotherapy. J Chemother2009; 21(5): 475-81.
28.
OsthoffMSiegemundMBalestraGAbdul-AzizMHRobertsJA. Prolonged administration of β-lactam antibiotics - a comprehensive review and critical appraisal. Swiss Med Wkly2016; 10; 146: w14368.
29.
TumbarelloMVialePViscoliCet al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumonia carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis2012; 55(7): 943-50.
30.
PetrosilloNGiannellaMLewisRVialeP. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther2013; 11(2): 159-77.
31.
GilbertDN. Aminoglycosides, In: MandellGLBennettJEKolin RR, eds. Principles and Practice of Infectious Diseases. Philadelphia, PA: Churchill Livingstone2000: 307-36.
32.
DrusanoGLAmbrosePGBhavnaniSMBertinoJSNafzigerANLouieA. Back to the Future:Using Aminoglycosides Again and How to Dose Them Optimally. Clin Infect Dis2007; 45: 753-60.
33.
MacGowanA. Revisiting Beta-lactams - PK/PD improves dosing of old antibiotics. Curr Opin Pharmacol2011; 11(5): 470-6.
34.
PerezFBonomoRA. Can we really use ß-lactam/ß-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ß-lactamase-producing bacteria?Clin Infect Dis2012; 15; 54(2): 175-7.
35.
López-CereroLPicónEMorilloCet al. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. Clin Microbiol Infect2010; 16(2): 132-6.
36.
BoucherHWTalbotGHBradleyJSet al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis2009; 48(1): 1-12.
37.
XiaoAJCaroLPopejoyMWHuntingtonJAKullarR. PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease. Infect Dis Ther2017; 6(1): 137-48.
38.
CraigWAAndesDR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother2013; 57(4): 1577-82.
39.
BerkhoutJMelchersMJvan MilACet al. Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection. Antimicrob Agents Chemother2015; 60(1): 368-75.
40.
KrappFGrantJLSuttonSHOzerEABarrVO. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation. Int J Antimicrob Agents2017; 49: 770-3.
41.
AppelbaumPCHunterPA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents2000; 16(1): 5-15.
42.
PetersonLR. Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity. Clin Infect Dis2001; 33(Suppl 3): S180-6.
43.
ShepherdAKPottingerPS. Management of urinary tract infections in the era of increasing antimicrobial resistance. Med Clin North Am2013; 97(4): 737-57.
44.
ZowawiHMHarrisPNRobertsMJet al. The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol2015; 12(10): 570-84.
45.
ModyLJuthani-MehtaM. Urinary tract infections in older women: a clinical review. JAMA2014; 311(8): 844-54.
46.
MazzeiTCassettaMIFallaniSArrigucciSNovelliA. Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. Int J Antimicrob Agents2006; 28 (Suppl 1): S35-41.
47.
KeatingGM. Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs2013; 73: 1951-66.
48.
ZhanelGGWalktyAJKarlowskyJA. Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis. Can J Infect Dis Med Microbiol2016; 2016: 2082693.
49.
NovelliARosiE. Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections. J Chemother2017; 29(Suppl 1): S10-8.
50.
KopaczJMarianoNColon-UrbanRet al. Identification of extended-spectrum-β-lactamase-positive Klebsiella pneumoniae urinary tract isolates harboring KPC and CTX-M β-lactamases in nonhospitalized patients. Antimicrob Agents Chemother2013; 57(10): 5166-9.
51.
MezzatestaMLLa RosaGMaugeriGet al. In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens. Int J Antimicrob Agents2017; 49(6): 763-6.
